华盛顿特区和约翰·霍普金斯大学艾滋病毒队列中整合酶抑制剂的处方差异
Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts.
作者信息
Monroe Anne K, Levy Matthew E, Greenberg Alan E, Keruly Jeanne C, Moore Richard D, Horberg Michael A, Kulie Paige, Mohanraj Bernadine S, Kumar Princy N, Castel Amanda D
机构信息
The George Washington University, Washington, DC, USA.
Westat, Rockville, Maryland, USA.
出版信息
Open Forum Infect Dis. 2021 Jul 27;8(8):ofab338. doi: 10.1093/ofid/ofab338. eCollection 2021 Aug.
Abstract
Integrase inhibitors (INSTIs) are recommended by expert panels as initial therapy for people with HIV. Because there can be disparities in prescribing and uptake of novel and/or recommended therapies, this analysis assessed potential INSTI prescribing disparities using a combined data set from the Johns Hopkins HIV Clinical Cohort and the DC Cohort. We performed multivariable logistic regression to identify factors associated with ever being prescribed an INSTI. Disparities were noted, including clinic location, age, and being transgender. Identifying disparities may allow clinicians to focus their attention on these individuals and ensure that therapy decisions are grounded in valid clinical reasons.
摘要
整合酶抑制剂（INSTIs）被专家小组推荐作为HIV感染者的初始治疗方案。由于新型和/或推荐疗法在处方和使用方面可能存在差异，本分析使用约翰·霍普金斯HIV临床队列和华盛顿特区队列的合并数据集评估了潜在的整合酶抑制剂处方差异。我们进行了多变量逻辑回归，以确定与曾接受整合酶抑制剂处方相关的因素。发现了一些差异，包括诊所位置、年龄和跨性别身份。识别这些差异可能使临床医生将注意力集中在这些个体身上，并确保治疗决策基于有效的临床理由。
相似文献
1
Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts.华盛顿特区和约翰·霍普金斯大学艾滋病毒队列中整合酶抑制剂的处方差异
Open Forum Infect Dis. 2021 Jul 27;8(8):ofab338. doi: 10.1093/ofid/ofab338. eCollection 2021 Aug.
2
Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).中国河南省整合酶抑制剂耐药突变体的流行情况（2018-2020 年）。
Infection. 2021 Dec;49(6):1195-1202. doi: 10.1007/s15010-021-01668-9. Epub 2021 Jul 19.
3
Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors.接受整合酶抑制剂治疗的 HIV 感染者的神经心理学表现改变和脑容量减少。
AIDS. 2019 Jul 15;33(9):1477-1483. doi: 10.1097/QAD.0000000000002236.
4
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.在一个大型的意大利队列中，暴露于整合酶抑制剂的 HIV-1 感染患者的耐药突变的流行率和决定因素。
HIV Med. 2019 Feb;20(2):137-146. doi: 10.1111/hiv.12692. Epub 2018 Nov 21.
5
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.在临床实践中，基于整合酶链转移抑制剂的治疗方案与有限的HIV-1 V3环进化相关。
Virus Genes. 2019 Jun;55(3):290-297. doi: 10.1007/s11262-019-01649-z. Epub 2019 Feb 22.
6
Primary resistance to integrase strand-transfer inhibitors in Europe.欧洲对整合酶链转移抑制剂的原发性耐药性。
J Antimicrob Chemother. 2015 Oct;70(10):2885-8. doi: 10.1093/jac/dkv202. Epub 2015 Jul 17.
7
Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis.2009年至2016年加拿大不列颠哥伦比亚省人类免疫缺陷病毒1型整合酶链转移抑制剂耐药性的流行情况：一项纵向分析。
Open Forum Infect Dis. 2019 Feb 12;6(3):ofz060. doi: 10.1093/ofid/ofz060. eCollection 2019 Mar.
8
Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.初治和经治的HIV-1感染患者中整合酶链转移抑制剂耐药突变的流行情况：单中心经验
AIDS Res Hum Retroviruses. 2018 Jul;34(7):570-574. doi: 10.1089/AID.2018.0006. Epub 2018 May 9.
9
Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.基于整合酶抑制剂的抗逆转录病毒疗法在感染HIV的女性中的应用：来自OPERA队列的数据。
Curr HIV Res. 2019;17(4):266-276. doi: 10.2174/1570162X17666190927161537.
10
Outcomes of Integrase Inhibitor-based Antiretroviral Therapy in a Clinical Cohort of Treatment-experienced Children, Adolescents and Young Adults With HIV Infection.基于整合酶抑制剂的抗逆转录病毒疗法在有 HIV 感染的治疗经验丰富的儿童、青少年和年轻成人临床队列中的结果。
Pediatr Infect Dis J. 2020 May;39(5):421-428. doi: 10.1097/INF.0000000000002577.
引用本文的文献
1
Prevention, treatment and cure of HIV infection.HIV 感染的预防、治疗和治愈。
Nat Rev Microbiol. 2023 Oct;21(10):657-670. doi: 10.1038/s41579-023-00914-1. Epub 2023 Jun 21.
2
Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US.美国艾滋病毒感染者初始抗逆转录病毒治疗中种族和民族与处方的关联。
JAMA. 2023 Jan 3;329(1):52-62. doi: 10.1001/jama.2022.23617.
本文引用的文献
1
HIV-related outcome disparities between transgender women living with HIV and cisgender people living with HIV served by the Health Resources and Services Administration's Ryan White HIV/AIDS Program: A retrospective study.卫生资源和服务管理局的“瑞安·怀特艾滋病防治计划”服务的艾滋病毒感染者中的跨性别女性与顺性别艾滋病毒感染者之间与艾滋病毒相关的结局差异：一项回顾性研究。
PLoS Med. 2020 May 28;17(5):e1003125. doi: 10.1371/journal.pmed.1003125. eCollection 2020 May.
2
HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals.HIV 抗病毒治疗和 HIV 暴露前预防在跨性别者中的应用。
Drugs. 2020 Jul;80(10):965-972. doi: 10.1007/s40265-020-01313-z.
3
Changes in HIV antiretroviral prescribing practices in the United States.美国艾滋病毒抗逆转录病毒治疗处方实践的变化。
Int J STD AIDS. 2020 Jan;31(1):22-29. doi: 10.1177/0956462419880127. Epub 2019 Dec 2.
4
Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study.初治抗逆转录病毒治疗个体启动多替拉韦、埃替拉韦、拉替拉韦或达芦那韦后的病毒学转归：一项观察性研究
Infect Dis Ther. 2020 Mar;9(1):41-52. doi: 10.1007/s40121-019-00274-5. Epub 2019 Nov 7.
5
2019 update of the drug resistance mutations in HIV-1.2019年人类免疫缺陷病毒1型耐药性突变的更新情况。
Top Antivir Med. 2019 Sep;27(3):111-121.
6
Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.埃替格韦、多替拉韦和拉替拉韦在初治和经治患者真实世界队列中的安全性和有效性。
Medicine (Baltimore). 2019 Aug;98(32):e16721. doi: 10.1097/MD.0000000000016721.
7
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.博茨瓦纳的神经管缺陷和抗逆转录病毒治疗方案。
N Engl J Med. 2019 Aug 29;381(9):827-840. doi: 10.1056/NEJMoa1905230. Epub 2019 Jul 22.
8
Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.在临床环境中，整合酶抑制剂在治疗经验丰富的患者中的疗效。
AIDS. 2019 Jun 1;33(7):1187-1195. doi: 10.1097/QAD.0000000000002194.
9
Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study.在真实临床环境中，与基于非核苷类和蛋白酶抑制剂的治疗方案相比，基于整合酶抑制剂的治疗方案能使初治人类免疫缺陷病毒感染患者的病毒学抑制率提高得更快：一项回顾性队列研究。
Medicine (Baltimore). 2018 Oct;97(43):e13016. doi: 10.1097/MD.0000000000013016.
10
Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system.拉替拉韦在HIV感染患者中的使用与长期健康结局的关联：一项在大型综合医疗系统中进行的上市后观察性安全性研究。
HIV Clin Trials. 2018 Oct;19(5):177-187. doi: 10.1080/15284336.2018.1523826. Epub 2018 Oct 27.
Zotero 插件